JP2008515775A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008515775A5 JP2008515775A5 JP2007525855A JP2007525855A JP2008515775A5 JP 2008515775 A5 JP2008515775 A5 JP 2008515775A5 JP 2007525855 A JP2007525855 A JP 2007525855A JP 2007525855 A JP2007525855 A JP 2007525855A JP 2008515775 A5 JP2008515775 A5 JP 2008515775A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- antibody
- years
- stable
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60131104P | 2004-08-13 | 2004-08-13 | |
| US60/601,311 | 2004-08-13 | ||
| PCT/US2005/028861 WO2006020935A2 (en) | 2004-08-13 | 2005-08-12 | Stabilizing formulations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008515775A JP2008515775A (ja) | 2008-05-15 |
| JP2008515775A5 true JP2008515775A5 (enExample) | 2011-11-10 |
| JP4948407B2 JP4948407B2 (ja) | 2012-06-06 |
Family
ID=35908214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007525855A Expired - Fee Related JP4948407B2 (ja) | 2004-08-13 | 2005-08-12 | 安定化処方 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8871201B2 (enExample) |
| EP (1) | EP1784219B1 (enExample) |
| JP (1) | JP4948407B2 (enExample) |
| KR (1) | KR20070092197A (enExample) |
| CN (1) | CN101022831A (enExample) |
| AR (1) | AR051009A1 (enExample) |
| AU (1) | AU2005272603A1 (enExample) |
| BR (1) | BRPI0514340A (enExample) |
| CA (1) | CA2575870A1 (enExample) |
| CR (1) | CR8904A (enExample) |
| EC (1) | ECSP077246A (enExample) |
| ES (1) | ES2637854T3 (enExample) |
| IL (1) | IL181265A0 (enExample) |
| MX (1) | MX2007001599A (enExample) |
| NO (1) | NO20070930L (enExample) |
| RU (1) | RU2007109062A (enExample) |
| TW (1) | TW200621282A (enExample) |
| WO (1) | WO2006020935A2 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| WO2006138181A2 (en) | 2005-06-14 | 2006-12-28 | Amgen Inc. | Self-buffering protein formulations |
| GEP20125628B (en) * | 2006-04-21 | 2012-09-10 | Novartis Ag | Pharmaceutical compositions containing antagonist anti-cd40 antibody |
| JP2009534390A (ja) * | 2006-04-21 | 2009-09-24 | アムジェン インコーポレイテッド | 生物医薬品製剤のための緩衝剤 |
| US20080070230A1 (en) * | 2006-06-12 | 2008-03-20 | Wyeth | Methods for reducing or preventing liquid-liquid phase separation in high concentration protein solutions |
| EP1950225A1 (de) * | 2007-01-25 | 2008-07-30 | Octapharma AG | Verfahren zur Steigerung von Proteinausbeuten |
| NZ598881A (en) * | 2007-03-29 | 2013-11-29 | Abbvie Inc | Crystalline anti-human il-12 antibodies |
| KR20210049186A (ko) * | 2007-11-30 | 2021-05-04 | 애브비 바이오테크놀로지 리미티드 | 단백질 제형 및 이의 제조방법 |
| US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
| MX2011005672A (es) * | 2008-11-28 | 2011-06-20 | Abbott Lab | Composiciones de anticuerpo estables y metodos para estabilizar a las mismas. |
| WO2010100135A1 (en) | 2009-03-05 | 2010-09-10 | Ablynx N.V. | Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof |
| US9265834B2 (en) | 2009-03-05 | 2016-02-23 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
| NZ595694A (en) * | 2009-05-04 | 2013-09-27 | Abbvie Biotechnology Ltd | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies |
| LT2805731T (lt) | 2009-09-03 | 2019-02-11 | Ablynx N.V. | Stabilios polipeptidų kompozicijos ir jų panaudojimas |
| MX421100B (es) | 2011-07-01 | 2025-02-10 | Biogen Ma Inc | Composiciones del polipeptido de fusion tnfr: fc exentas de arginina y metodos de uso |
| AU2012345768B2 (en) | 2011-11-30 | 2016-05-12 | Kindeva Drug Delivery L.P. | Microneedle device having a peptide therapeutic agent and an amino acid, methods of making and using the same |
| US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
| EP4527855A3 (en) * | 2012-03-26 | 2025-06-11 | Sanofi | Stable igg4 based binding agent formulations |
| US8883979B2 (en) | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| EP2934587A4 (en) * | 2012-12-18 | 2016-08-03 | Merck Sharp & Dohme | Liquid formulations for an anti-TNF-alpha-antibody |
| BR112016010051A2 (pt) | 2013-11-04 | 2017-12-05 | Pfizer | ?conjugados de anticorpo-fármaco anti-efna4? |
| RS67458B1 (sr) | 2014-03-28 | 2025-12-31 | Univ Duke | Lečenje kancera dojke pozitivnog na receptor estrogena upotrebom selektivnih modulatora receptora estrogena |
| GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| WO2016014546A1 (en) * | 2014-07-21 | 2016-01-28 | Unchained Labs Inc. | Determination of protein aggregation from the concentration dependence of delta g |
| KR102676629B1 (ko) | 2015-04-29 | 2024-06-18 | 래디어스 파마슈티컬스, 인코포레이티드 | 암을 치료하는 방법 |
| GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
| GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
| GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
| IL264640B2 (en) | 2016-08-18 | 2024-03-01 | Regeneron Pharma | Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopy |
| ES3064802T3 (en) | 2016-10-21 | 2026-04-29 | Amgen Inc | Pharmaceutical formulations and methods of making the same |
| KR102881465B1 (ko) | 2017-01-05 | 2025-11-04 | 래디어스 파마슈티컬스, 인코포레이티드 | Rad1901-2hcl의 다형 형태 |
| CN112423844B (zh) | 2018-07-04 | 2024-08-13 | 雷迪厄斯制药公司 | Rad1901-2hcl的多晶型形式 |
| JOP20210218A1 (ar) | 2019-02-12 | 2023-01-30 | Radius Pharmaceuticals Inc | عمليات ومركبات |
| AU2021262609A1 (en) * | 2020-05-01 | 2022-12-22 | Kashiv Biosciences, Llc | An improved process of purification of protein |
| US20240059768A1 (en) * | 2021-01-14 | 2024-02-22 | Hanall Biopharma Co., Ltd. | A stable ophthalmic composition comprising tanfanercept, which is free of stabilizer or substantially free of stabilizer |
| CN115541895B (zh) * | 2022-11-29 | 2023-05-19 | 天津德祥生物技术股份有限公司 | 一种提高微流控反定检测卡灵敏度的配方液及应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0041768B1 (en) * | 1980-04-24 | 1987-11-11 | Beecham Group Plc | Beta-lactam compounds, their preparation and use |
| GB8518416D0 (en) | 1985-07-22 | 1985-08-29 | Beecham Group Plc | Compounds |
| US5869053A (en) * | 1988-03-04 | 1999-02-09 | Cancer Research Campaign Technology, Ltd. | 5T4 antigen from human trophoblasts |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| US6306393B1 (en) * | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| AU747602B2 (en) * | 1997-06-04 | 2002-05-16 | Oxford Biomedica (Uk) Limited | Vector |
| EP0999853B1 (en) | 1997-06-13 | 2003-01-02 | Genentech, Inc. | Stabilized antibody formulation |
| WO1999037329A1 (en) | 1998-01-22 | 1999-07-29 | Astrazeneca Ab | Pharmaceutical formulation comprising an antibody and a citrate buffer |
| JP4516711B2 (ja) * | 1999-12-28 | 2010-08-04 | 中外製薬株式会社 | 安定な抗体組成物及び注射製剤 |
| JP5485489B2 (ja) | 2000-08-11 | 2014-05-07 | 中外製薬株式会社 | 抗体含有安定化製剤 |
| JP4340062B2 (ja) * | 2000-10-12 | 2009-10-07 | ジェネンテック・インコーポレーテッド | 粘度の減少した濃縮タンパク質製剤 |
| GB0113179D0 (en) * | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
| WO2003057163A2 (en) * | 2002-01-03 | 2003-07-17 | Smithkline Beecham Corporation | Methods for preparing immunoconjugates |
| SG187991A1 (en) * | 2002-05-02 | 2013-03-28 | Wyeth Corp | Calicheamicin derivative-carrier conjugates |
| EP1551875A4 (en) * | 2002-06-21 | 2006-06-28 | Biogen Idec Inc | TAMPON PREPARATIONS FOR CONCENTRATING ANTIBODIES AND METHODS FOR USE THEREOF |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| JP2007528868A (ja) * | 2003-08-14 | 2007-10-18 | ワイス | 抗ルイスｙ抗イディオタイプ抗体およびその使用 |
| US20060088522A1 (en) * | 2004-09-10 | 2006-04-27 | Wyeth | Humanized anti-5T4 antibodies and anti-5T4/calicheamicin conjugates |
-
2005
- 2005-08-11 TW TW094127308A patent/TW200621282A/zh unknown
- 2005-08-12 EP EP05803522.1A patent/EP1784219B1/en not_active Expired - Lifetime
- 2005-08-12 US US11/203,367 patent/US8871201B2/en active Active
- 2005-08-12 CN CNA2005800274833A patent/CN101022831A/zh active Pending
- 2005-08-12 RU RU2007109062/13A patent/RU2007109062A/ru not_active Application Discontinuation
- 2005-08-12 KR KR1020077003502A patent/KR20070092197A/ko not_active Withdrawn
- 2005-08-12 BR BRPI0514340-3A patent/BRPI0514340A/pt not_active IP Right Cessation
- 2005-08-12 JP JP2007525855A patent/JP4948407B2/ja not_active Expired - Fee Related
- 2005-08-12 AU AU2005272603A patent/AU2005272603A1/en not_active Abandoned
- 2005-08-12 WO PCT/US2005/028861 patent/WO2006020935A2/en not_active Ceased
- 2005-08-12 MX MX2007001599A patent/MX2007001599A/es unknown
- 2005-08-12 CA CA002575870A patent/CA2575870A1/en not_active Abandoned
- 2005-08-12 ES ES05803522.1T patent/ES2637854T3/es not_active Expired - Lifetime
- 2005-08-16 AR ARP050103456A patent/AR051009A1/es unknown
-
2007
- 2007-02-06 CR CR8904A patent/CR8904A/es not_active Application Discontinuation
- 2007-02-11 IL IL181265A patent/IL181265A0/en unknown
- 2007-02-13 EC EC2007007246A patent/ECSP077246A/es unknown
- 2007-02-19 NO NO20070930A patent/NO20070930L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2007109062A (ru) | Стабилизирующие препараты | |
| Arakawa et al. | Biotechnology applications of amino acids in protein purification and formulations | |
| ES2338218T3 (es) | Formulacion farmacologica liofilizada estable de anticuerpos igg daclizumab. | |
| S Rajan et al. | Chemical and pharmacological chaperones: application for recombinant protein production and protein folding diseases | |
| JP2010513522A5 (enExample) | ||
| JP2016534052A5 (enExample) | ||
| AR076748A1 (es) | Formulaciones estables de anticuerpos anti-tnf-alfa humanos con grandes concentraciones de proteinas. metodo de tratamiento | |
| US12251474B2 (en) | Process for lyophilized pharmaceutical formulations of a therapeutic protein | |
| WO2007147001A3 (en) | Lyophilized formulations of anti-egfr antibodies | |
| AR067011A1 (es) | Formulaciones de anticuerpos | |
| WO2008116103A3 (en) | Stable antibody formulations | |
| AR082257A1 (es) | Composicion de inmunoglobulinas humanas concentradas, procedimiento | |
| KR20060017583A (ko) | 고농도 항체 및 단백질 제형 | |
| RU2011127913A (ru) | Составы, содержащие антитела | |
| SI2236154T1 (en) | THE FORM OF IMUNOGLOBULIN AND THE METHOD OF ITS PREPARATION | |
| WO2013134626A1 (en) | Prevention and treatment of respiratory infection with peroxisome proliferator activator receptor delta agonist | |
| JP2007534698A5 (enExample) | ||
| KR20200144120A (ko) | 열 안정성을 개선하기 위한 단백질 제제에 대한 첨가제 | |
| RU2014112343A (ru) | Оставы антигенов staphylococcus aureus, содержащие адъюванты | |
| WO2006094974A3 (en) | Chemically defined stabiliser composition | |
| RU2018129077A (ru) | Стабильная фармацевтическая композиция | |
| JP2023518066A5 (enExample) | ||
| KR102237885B1 (ko) | 감소된 산화를 갖는 제제 | |
| CA2872275C (en) | Stabilized formulations containing anti-dll4 antibodies | |
| JP2019532267A5 (enExample) |